Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blocking drugs (ARB) block the effect of angiotensin II by different mechanisms. It has been suggested that combined therapy may be more effective at reducing blood pressure (BP) than higher doses of either drug.
Introduction
Angiotensin II (Ang II) is an important controller of arterial tone and sodium reabsorption, and drugs that block its formation or its action have become important in the therapy of hypertension and other cardiovascular disorders. [1] [2] [3] Its formation can be inhibited by drugs that block the conver-sion of angiotensin I (Ang I) to Ang II and angiotensin-converting enzyme (ACE) inhibitors have become important agents for the treatment of high blood pressure (BP). 1 The other therapeutic regime available at present is to block the binding of Ang II to the Ang II type I (AT 1 ) receptor. Both groups of agents block the effect of Ang II and are effective agents to lower BP. There are also other beneficial effects on cardiovascular disease. [4] [5] [6] While both groups of drugs are effective, there are powerful physiological compensations which may reduce the drug's effectiveness. With both groups of drugs, plasma renin rises, due to blockade of the short loop feedback of Ang II on renin secretion. 7 This causes a high level of Ang I in plasma, which can then compete with the ACE inhibitor (ACE-I) for binding to ACE, with the results that Ang II levels return towards normal. With an AT 1 receptor blocker (ARB), Ang II levels become elevated and can potentially overcome the competitive blockade of the AT 1 receptor, though some members of this group are claimed to have insurmountable antagonism. 8, 9 The question exists whether combined use of these two drug classes may have a more potent action than maximum doses of either drug class alone. 10 In rats, there is a synergistic effect by combining low doses of both drugs and a small, but less than additive, effect by combining large doses of each drug class. 11, 12 Rats used in experiments are inbred and have similar genetic composition and thus would be expected to respond in a similar fashion. In humans the situation is different.While ACE is the major pathway of converting Ang I to Ang II, there are also alternative tissue conversion pathways. 13, 14 An individual may have high levels of these alternative pathways and thus may not respond to ACE inhibition but could respond to an ARB. Individuals may have different concentrations of AT 1 -receptors or a different ratio of AT 1 :AT 2 -receptors and thus may not respond to an AT 1 -receptor blocking drug, but could respond to an ACE-I. 15 Elderly patients generally have low-renin levels, but theoretically the combination of ACE-I and ARB may achieve better BP control, by producing more complete blockage of Ang II via AT 1 blockade, coupled with kinin potentiation via the ACE-I.
The primary objective of this study was to determine if the fall in 24-hour systolic BP on the combination of an ACE-I and an ARB drug was
greater than the fall achieved with plateau doses given as monotherapy. The study was performed in a crossover design and thus differences in response to the different drug classes could be determined.
Methods
Patients aged 65 years or more, all of whom had been previously treated for hypertension, were recruited to the study. Patients had required two or more drugs for BP control, or were not adequately controlled on one drug. Patients gave informed consent and stopped their previous medication three to seven days before the randomisation visit. This therapy cessation was not to determine a baseline or entry BP, but to exclude patients who had an excessive rise in BP or felt unwell off therapy, as in such circumstances it was not ethical to have a four-week placebo period. The study was approved by the Ethics Committee of the Austin and Repatriation Medical Centre.
The study was a double-blind, randomised, crossover study with six treatment periods. The treatment periods were Period A -placebo four weeks; Period B -candesartan 16 mg for four weeks; Period C -candesartan 32 mg for four weeks; Period D -lisinopril 20 mg for four weeks; Period E -lisinopril 40 mg for four weeks; Period F -candesartan 16 mg and lisinopril 20 mg for four weeks.The study was of an incomplete factorial design. Patients took their medication daily at approximately 0800 hours. The patients were seen every four weeks and the following protocol was performed at each visit: On the day of their clinic visit, patients did not take their medication and attended between 0730 and 0800 hours. BP was taken at the clinic using the A & D model TM 2541R (A and D Company, Tokyo, Japan). Supine BP was recorded three times at one-minute intervals after resting for seven minutes. The patient then stood and the BP was recorded immediately and one minute later. An ambulatory BP (ABP) recorder was then fitted (A & D 2421 -A and D Company, Tokyo, Japan) and patients took their medication. This was completed prior to 0900 hours. BPs on the monitor prior to 0900 hours were discarded. BP was recorded every 20 minutes day and night. The next day, patients reported to the clinic at 0900 hours. The clinic pressures were recorded in a similar fashion to day one and the ABP recorder was removed. If the ABPM was unsatisfactory (i.e. less than 22 hours of recorded data), the therapy was continued and the procedure repeated within one week. At every visit, patients were weighed and had blood taken for urea, creatinine and electrolytes and for measurement of plasma renin activity (PRA) and aldosterone. Patients were also asked to indicate on an analogue scale of 1-8 their feeling of wellbeing and were asked whether they had experienced any adverse effects since their last visit. Alterations in other drug therapies were recorded.
In the 24 hours prior to the randomisation visit, patients provided a 24-hour urine collection while off therapy. Urinary Na + , K + , creatinine, urea and albumin were measured. If patients had a urinary albumin > 20 µgm/min at the randomisation visit, they had a 24-hour urine collection made at the end of each period on the day of the ABP recording.The same variables were determined on each specimen and the albumin excretion rate, glomerular filtration rate (creatinine clearance) and urea excretion rate were determined.
Patients were excluded from the study if BP rose excessively (greater than 190/100 mmHg) or if they had symptoms off therapy. Patients with a history of vascular problems (myocardial infarction, angina, transient ischaemic attacks or stroke) in the previous six months, were not included. Patients with a serum creatinine > 0.15 mmol/L or a potassium > 4.5 mmol/L were not randomised. An important entry criteria for evaluation was that while on placebo during the study, patients were required to have a 24-hour mean systolic BP > 135 mmHg and a day time mean systolic BP > 140 mmHg. This was a planned, prospective, inclusion criteria which could not be applied until the study was complete. Patients who did not meet this criteria were included in the safety and side-effect analysis but not in the effectiveness of agents for BP control. The 24-hour mean ambulatory BP was recorded for each drug and each dose. The 24-hour recording was divided into daytime recording (0900-2200 hours), sleep recording (0000-0600 hours) and morning (0600-0900 hours).
Comparison between the different periods and drug dosage was made by analysis of variance and paired t-test. For the analysis of variance, BP of individuals for each hour of the day on each therapy was obtained and used to determine the response at each hour. The analysis of variance included the time of day and the drug. It was first conducted with the placebo pressures included and subsequently with the placebo values excluded.The power calculations indicated that to detect a 5 mmHg difference in systolic BP with 80% power required 24 patients.
Results
Twenty-eight patients were asked to participate in the study and stopped antihypertensive medication. One person had an excessive rise in BP and felt unwell and was excluded from the study. One other patient declined to be randomised. Both patients returned to their previous therapy. Twenty-six patients (25M, 1F) were randomised to the study. Two withdrew before the first visit and are not included in the analysis. One patient was withdrawn after completing five of the six periods (missed lisinopril 40 mg) because of inadequate control and symptoms ascribed to this lack of BP control.This patient is included in the analysis, and the values on lisinopril 20 mg were also used for the lisinopril 40 mg treatment. One patient who completed all periods had a 24-hour mean systolic BP < 135 mmHg and a daytime BP < 140 mmHg on placebo and so is not included in the analysis. Thus, the analysis is based on 23 patients.
The demographics of the patients are indicated in Table 1 .All patients had been previously treated, with more than two-thirds requiring two or more drugs. At randomisation, when most people had been off therapy for 3-5 days, the supine BP was 160/88 mmHg, with the supine systolic BP ranging from 140-189 mmHg. The plasma creatinine was 0.11+0.01 mmol/L, the creatinine clearance was 77+6 ml/min. Twenty-four hour urinary sodium was 138+12 mmol/d and the albumin excretion was 40+19 µg/min, as determined from a 24-hour urine collection. Eight patients (two diabetic) had urine albumin excretion above the normal range. The clinic BPs on day 1 and 2 of each period were not different (p>0.3). Thus, the values have been combined and are indicated in Table 2 . All drugs reduced the clinic BP compared with placebo (p<0.001). The systolic and diastolic BP, supine and erect, at the clinic were higher on lisinopril 20 mg than on lisinopril 40 mg (Sys p=0.005 and 0.016; Diast p=0.015 and 0.007) and on the combination of candesartan 16 mg and lisinopril 20 mg (Sys p=0.014 and 0.046; Diast p=0.022 and 0.01). The other clinic values on active treatment did not differ from each other (p>0.2). There were no significant changes in pulse rate with any treatment. With assumption of the upright posture, systolic BP altered by approximately the same amount on both placebo and each of the drugs (-4.0+1.6 mmHg with placebo; -2.6 to -6.0 mmHg with active treatment) and diastolic BP was not significantly altered. One patient in the study had postural hypotensive symptoms while on lisinopril 40 mg, with a fall in BP on standing of 40/16 mmHg.
Twenty-four hour ambulatory BP measures were completed in the 23 eligible patients, but one patient missed the lisinopril 40 mg period. Most subjects had values for awake, sleep, morning and 24-hour BP but data was lacking for some periods in a few patients. The mean results for 24-hour, awake, sleep and morning BP and pulse rate are given in Table 3 . All BP values on all active treatments were significantly less than on placebo. The systolic and diastolic BP recorded over 24 hours and at all time periods on candesartan 16 and 32 mg did not differ from each other. The systolic BP on lisinopril 20 and 40 mg were similar and not different from the values on candesartan 16 and 32 mg. The 24-hour diastolic BP on lisinopril 40 mg tended to be lower than values on candesartan 16 mg (2.7 mmHg p=0.001), candesartan 32 mg (2.4 mmHg p=0.004) and lisinopril 20 mg (2.6 mmHg p=0.001) and a similar trend was noticed for awake and sleep diastolic BP.
The systolic BPs on combination therapy over 24 hours and at each time period were less than the values recorded on monotherapy (Table 3) and at most hourly (not shown, 17 out of 24) or two hourly periods (11 out of 12) ( Figure 1 ) they were less than the values on monotherapy.
The differences in 24-hour systolic BP on the combination compared with the other treatment PAPER Mean; sem All systolic and diastolic BP supine and erect on therapy are lower than on placebo p<0.01 * p<0.02 compared with lisinopril 40 mg and the combination. This p value is not corrected for multiple comparison. Table 4 and two way ANOVA for a difference between drug periods (i.e. placebo excluded) was significant at p<0.00001. Diastolic BP showed the same trend, but the differences did not always reach significance.
The fall in systolic BP occurred at the three time periods analysed. The fall during sleep ranged from 10.7 to 17.8 mmHg, compared with a daytime fall ranging from 10.2 to 15.3 mmHg. When corrected for the systolic BP on placebo (daytime=166; night time 146 mmHg), this implies a greater response at night. This was seen with all therapies, but was more prominent with lisinopril and the combination than with candesartan (Table 3, Figure 1 ). There were small differences in pulse rate (Table 3 ) and the 24-hour pulse rate on the combination was less than on placebo (2.5+0.5 b/min).This was due to a greater fall in pulse rate during the sleep and morning periods (4.2+0.7; 4.3+0.4 b/min) than during the day (1.3+0.6 b/min). There were minor variations with the other therapies and all therapies reduced the sleep pulse rate (Table 3) , though not all changes reached significance.
A comparison was also made of the fall in BP with the combination compared with the better of the two responses to the same dose of monotherapy as used in the combination. The fall in 24-hour BP with the combination was PAPER Mean; sem n=20 to 23 for each variable. All blood pressure values less than corresponding placebo. Analysis of variance indicated effects of the drugs compared with placebo for systolic and diastolic BP (p<0.00001). With placebo period deleted ANOVA indicated a difference between the drug classes for systolic BP (p<0.0001). Similar differences existed for day and sleep systolic BP (see Table 4 ). Pulse rates not different. Day = 9.00 am -10.00 pm; Night = Midnight -6.00 am; Morning = 6.00 am -9.00 am Load is Sys > 140 mmHg day; > 120 mmHg night; Diastolic > 90 mmHg day; > 85 mmHg night.
Figure 1
The change in systolic blood pressure from placebo over a 2-hourly period is plotted for the different treatments. Result for C16 and C32 mg have been combined, as have the results for L20 and L40 mg The difference between the falls was 3.3+1.0/1.3+0.4 mmHg in favour of the individual monotherapies with a p value < 0.01 for both systolic and diastolic BP. Plasma renin concentration rose with all active therapies ( Table 5 ). The PRA on candesartan 16 and 32 mg did not differ. The PRA on lisinopril 20 and 40 mg did not differ from each other and were not different from the values on candesartan. The PRA on the combination was similar to that on the other therapies. Plasma aldosterone fell with each of the therapies, but the combination caused no greater fall than either monotherapy ( Table 5) .
Three patients in the study were of particular interest ( Table 6 ). One (Patient A) had no response to either dose of lisinopril but responded excellently to both doses of candesartan. PRA rose on candesartan but on both doses of lisinopril was not different from placebo (Table 6 ). A second (Patient B) had a similar, but not as large, response to candesartan but no fall with lisinopril. Plasma renin rose on candesartan but not on lisinopril. One other patient (Patient C) had the opposite response. There was a comparatively small fall in BP with both doses of candesartan with only a small rise in renin. With lisinopril in both doses, the falls in BP were greater and the rises in PRA were larger ( Table 6 ). The response to the combination was similar to that of the better drug in the three patients. The improvement in response due to these three patients accounted for more than 50% of the better response to the combination.
Eight patients had elevated albumin in their urine and 24-hour urine collections were made on those patients at each visit. The 24-hour creatinine and urea clearances were not altered significantly by any of the active treatments, though there was a trend (p=0.1) for creatinine clearance to fall with lisinopril 40 mg/d. The effects of the therapies on urinary albumin excretion are indicated in Figure 2 .All active therapies reduced the excretion of albumin and the excretion of albumin was lowest on the combination, though this difference did not reach statistical significance.
From the questionnaire of wellbeing, the mean score on placebo and each therapy was approximately 5.5 out of eight and did not differ between any of the periods. Side-effects on the different drugs were infrequent and the drugs were well tolerated. Plasma sodium, chloride, bicarbonate and urea were not altered in any of the therapeutic arms ( Table 7) . Plasma K + rose on active therapy and the rise was greatest (0.24+0.08 mmol/L) in patients on combination therapy. Four patients on combination treatment had plasma K + 
Discussion
The aim of this study was to determine whether the combination of an ACE-I and an ARB had a greater effect than higher doses of either drug as monotherapy in elderly hypertensive patients. To evaluate this proposition requires that the combination used is compared with maximum effective doses of each drug. These criteria appeared to be fulfilled as the responses to candesartan 16 and 32 mg were similar in all BP measurements and in the various subdivisions of the day. In addition there was a similar elevation of renin on both doses, which suggests that a plateau was reached with 16 mg/day. Overall a similar conclusion was reached with lisinopril, though lisinopril 40 mg caused an equivocally significant greater fall in clinic systolic and diastolic BP and 24-hour diastolic BP than lisinopril 20 mg. However, the 24-hour fall in systolic BP and rise in renin were similar, suggesting that in this group of patients a plateau effect was achieved with lisinopril 20 mg/day. The BP levels achieved in all the day's subdivisions were lower on the combination than on either of the two monotherapies. The additional, effect, though significant, was relatively small and was less than additive (i.e. 3-4 mmHg instead of 12 mmHg). This is in contrast to studies using a similar design comparing, in one study, candesartan, felodipine and their combination and, in the other, felodipine with enalapril and their combination. In a similar number of patients, a full additive effect of the combination was observed. 16, 17 The results are similar to our studies in rats of the effect of combining ACE-I and ARBs. 11, 12 When low doses of both are combined, the effect on peak BP response is more than additive (i.e. synergistic).When plateau doses of the two drug classes were used, there was a slightly greater fall in BP with the combination than with maximum doses of either drug as monotherapy. In that study, the ACE-I also had a slightly greater BP-lowering effect than the ARB. In rats, results are likely to be similar since inbred strains are used, but in humans the genotypes and phenotypes are variable and other reasons may exist for differences in response. In this study, the overall 24-hour falls with lisinopril and candesartan were similar, but there was a trend for the fall during sleep with lisinopril to be greater than with candesartan and this was also when the combination was most effective. The fall during sleep was greater than the fall during the awake hours, despite a lower BP on placebo.
Three patients were of particular interest. Two patients responded better to both doses of candesartan, the third to both doses of lisinopril. In the patients who responded to candesartan, but not lisinopril, PRA rose markedly on candesartan, but was not different from placebo on lisinopril. This suggests that alternate pathways of Ang II formation were very active, thus an ACE-I may not prevent Ang II formation. 13, 14 In the other patient, the reverse response occurred, suggesting that the ARB was not able to prevent Ang II action, possibly due to high production rates of Ang II adjacent to the AT 1 receptor. 18, 19 In a previous study, Sever and Chang 15 suggested that different people might respond to ACE-I compared to ARB. It was difficult in that study to determine whether the result was due to spontaneous variation. Our results suggest that some people do respond differently and the recruitment of additional responders explained more than 50% of the additional fall in BP with the combination. In addition to the three patients reported, there were other individuals who appeared to respond better to candesartan than lisinopril and vice versa, but this could be random variation.
Combination therapy may lower BP more than monotherapy for two reasons.There may be a true additive effect of both drugs so that most patients have an additional fall in BP, and thus the combination is more effective than either drug alone. The other reason for the combination appearing to be more effective is that certain people respond to one drug and not to the other. In parallel designed studies, it is impossible to determine which of the above is the case. This can only be done in a four-way crossover study in which placebo, the individual monotherapies and combination therapy are used. The statistical comparison is between the response with the combination and the better of the two responses with monotherapy. This analysis is biased by chance against the combination, but if positive it means there is a true additive effect. In studies 16, 17 of a dihydropyridine calcium blocking drug and either an ACE-I or an ARB, a statistically significantly greater fall in BP was found with the combination. In this study, the fall in BP with the better of the two monotherapies was greater than achieved with combination therapy, with a p value < 0.01. This significance is due to the artificial selection of the better response, but the result implies that there is no additive effect of the two agents but recruitment of people who respond to one drug and not the other.
Superficially, the results of this study appear to confirm the results of the Candesartan And Lisinopril Microalbuminuria (CALM) 10 and other studies. [20] [21] [22] In most studies, the additional fall in BP with the combination has been similar to that seen in this study of about 4/3 mmHg. The exception was the CALM study, 10 in which the additional fall was about 10/6 mmHg. However, in that study they did not add the second drug to people who had had a good response to the first drug; thus, the response would be exaggerated, as they would have a greater pool of non-responders to whom the other drug was added. While the additional changes in BP with combination therapy are similar, the use of a double-blind crossover study allows a different interpretation and conclusion to be reached which would have an important impact on clinical practice. None of the above studies have the three arms in the same patient (i.e. both monotherapies and combination therapy), which is essential to determine if there is an individual patient additive effect. Thus, we expect the results are due to recruitment of people who respond to one drug and not the other, or alternatively that the ACE inhibition was not at its plateau response when candesartan was added. 10, [20] [21] [22] Alternatively, patients with renal disease may have an activated intrarenal renin angiotensin system that could not be completely blocked with one type of drug in the doses used. 23 A recent study by Azizi et al. 24 is of interest. This study reported, in an appropriate four-way crossover design, the response to a single dose of placebo, fosinopril 20, irbesartan 300 mg and fosinopril 20 + irbesartan 150 mg. The study was performed in patients on a high salt intake. They demonstrated that the fall in BP at peak in these normotensive people with combination therapy was greater than the fall with either monotherapy. However, 24 hours post dose there were no significant falls in BP and no differences between the drugs. No analysis is provided related to individual patients' response. The extent of blockade of renin release as assessed by PRA varied, with the combination, irbesartan 300 mg and fosinopril 20 mg increasing PRA in that order. Thus, it is probable that in this high salt intake normotensive model, the doses of fosinopril and irbesartan used were not maximal and higher doses may have gained the same response.
Both drugs reduced albuminuria and the combination achieved the lowest urinary excretion rate, though the value was not significantly lower than on either monotherapy. Kincaid-Smith et al., 22 in an open study, reported an additive effect both on BP and on albumin excretion rate. The patients in that study had much greater proteinuria and were probably not on plateau doses of ACE-Is.
In this group of elderly hypertensive patients with some impairment of renal function related to age and hypertension but not to specific renal disease, both drugs were well tolerated in maximal doses. There were minor increases in plasma creatinine with both drugs and the combination, but no patient had significant deterioration of renal function. Likewise, plasma K + increased but in no person to dangerous levels. The individual drugs and the combination (even in plateau doses of both) were well tolerated.
In most non-diabetic, elderly patients, it does not appear justified to add an ACE-I to an ARB or vice versa to lower BP further. A greater effect can be achieved by adding a diuretic or a calcium channel blocker than by this combination. However, it appears that there are some individuals who may respond to one drug class and not the other 15 and thus, in a person in whom blockade of the renin angiotensin system is required and one drug class has not been effective, it may be justified to replace it with a drug from the other class. This conclusion applies to the effect on BP and it is possible that in patients with cardiac failure and other end-organ damage, different results may be obtained. 
